Aydin Ahmet, Katlan Banu, Kesici Selman
Hacettepe University - Department of Cardiovascular Surgery, Ankara - Turquia.
Hacettepe University - Department of Pediatric Critical Care Medicine, Ankara - Turquia.
Arq Bras Cardiol. 2025 Jul 7;122(5):e20250070. doi: 10.36660/abc.20250070. eCollection 2025.
A vasoplegic syndrome is a state of hypotension that develops due to low systemic vascular resistance and is associated with a high mortality rate. Methylene blue is known to improve hypotension and reduce vasopressor requirements by increasing resistance in vasoplegia by inhibiting nitric oxide synthase. Here, we aimed to report on the use and effectiveness of methylene blue to treat severely hypotensive five vasoplegic syndrome cases despite extracorporeal membrane oxygenation. We concluded that Methylene blue can be used as a lifesaving treatment for vasoplegic syndrome refractory to standard supportive treatments, including ECMO.
血管麻痹综合征是一种由于全身血管阻力降低而导致的低血压状态，且死亡率很高。已知亚甲蓝可通过抑制一氧化氮合酶来增加血管麻痹时的血管阻力，从而改善低血压并减少血管升压药的使用。在此，我们旨在报告亚甲蓝在体外膜肺氧合（ECMO）支持下治疗5例严重低血压血管麻痹综合征患者的应用情况及疗效。我们得出结论，亚甲蓝可作为一种挽救生命的治疗方法，用于治疗包括ECMO在内的标准支持治疗无效的血管麻痹综合征。
